 |
 |
 |
|
|
|
|
|
|
Tissue Array Specification Sheet
| Product Name: | Multiple organ squamous cell carcinoma tissue array, 63 cases/63 cores 3 Slides Price: $568 , 5 Slides Price: $927 |
|---|
| Array Panel: | Multiple organ squamous cell carcinoma tissue microarray, single core per case with 63 cases of squamous cell carcinoma (bladder, breast, ear, esophagus, eye, gallbladder, gingiva, kidney, larynx, lip, lung, nasopharynx, nose, ovary, penis, pharynx, rectum, salivary gland, skin, stomach, thymus, tongue, ureter, uterus and vulva) |
|---|
| Cat No. |
Cases |
Layout |
Cores |
Diameter |
Thickness |
Standard IHC |
| BC00019 |
63 |
7 x 9 |
63 |
1.5 mm |
5 µm |
Anti-Cytokeratin (CK) confirmed |
Microarray Panel Display | Legend: | Bla - Bladder,
Bre - Breast,
Ear - Ear,
Eso - Esophagus,
Eye - Eye,
Gal - Gallbladder,
Gin - Gingiva,
Kid - Kidney,
Lar - Larynx,
Lip - Lip,
Lun - Lung,
Nas - Nasopharynx,
Nos - Nose,
Ova - Ovary,
Pen - Penis,
Pha - Pharynx,
Rec - Rectum,
Sal - Salivary gland,
Ski - Skin,
Sto - Stomach,
Thy - Thymus,
Ton - Tongue,
Ure - Ureter,
Ute - Uterus,
Vul - Vulva
 - Malignant tumor
|
Specification Sheet
| Pos |
No. |
Sex |
Age |
Organ |
Pathology diagnosis |
Grade |
Type † |
| A1 |
1 |
M |
37 |
Skin |
Squamous cell carcinoma |
I |
Malignant |
| A2 |
2 |
M |
62 |
Esophagus |
Squamous cell carcinoma (sparse) |
III |
Malignant |
| A3 |
3 |
M |
56 |
Larynx |
Squamous cell carcinoma |
I |
Malignant |
| A4 |
4 |
M |
51 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
| A5 |
5 |
M |
36 |
Gingiva |
Squamous cell carcinoma |
I |
Malignant |
| A6 |
6 |
M |
43 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
| A7 |
7 |
F |
49 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
| A8 |
8 |
F |
29 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
| A9 |
9 |
M |
52 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
| B1 |
10 |
M |
85 |
Skin |
Squamous cell carcinoma |
I |
Malignant |
| B2 |
11 |
M |
66 |
Esophagus |
Squamous cell carcinoma |
II |
Malignant |
| B3 |
12 |
M |
71 |
Larynx |
Squamous cell carcinoma |
II |
Malignant |
| B4 |
13 |
M |
65 |
Lung |
Squamous cell carcinoma |
I |
Malignant |
| B5 |
14 |
M |
55 |
Gingiva |
Squamous cell carcinoma |
III |
Malignant |
| B6 |
15 |
M |
47 |
Penis |
Cancer adjacent tissue (chronic inflammation) |
- |
Malignant |
| B7 |
16 |
F |
55 |
Uterine cervix |
Squamous cell carcinoma |
III |
Malignant |
| B8 |
17 |
F |
42 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
| B9 |
18 |
F |
68 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
| C1 |
19 |
F |
78 |
Skin |
Squamous cell carcinoma |
III |
Malignant |
| C2 |
20 |
F |
46 |
Esophagus |
Squamous cell carcinoma |
III |
Malignant |
| C3 |
21 |
M |
62 |
Larynx |
Squamous cell carcinoma |
II |
Malignant |
| C4 |
22 |
M |
73 |
Lung |
Squamous cell carcinoma |
I |
Malignant |
| C5 |
23 |
M |
49 |
Tongue |
Squamous cell carcinoma |
II |
Malignant |
| C6 |
24 |
M |
60 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
| C7 |
25 |
F |
56 |
Uterine cervix |
Squamous cell carcinoma |
I |
Malignant |
| C8 |
26 |
F |
46 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
| C9 |
27 |
M |
38 |
Stomach |
Squamous cell carcinoma |
II |
Malignant |
| D1 |
28 |
F |
90 |
Skin |
Squamous cell carcinoma |
II |
Malignant |
| D2 |
29 |
M |
66 |
Esophagus |
Squamous cell carcinoma |
I |
Malignant |
| D3 |
30 |
M |
56 |
Larynx |
Squamous cell carcinoma |
III |
Malignant |
| D4 |
31 |
M |
64 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
| D5 |
32 |
F |
52 |
Lip |
Squamous cell carcinoma |
II |
Malignant |
| D6 |
33 |
M |
70 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
| D7 |
34 |
F |
46 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
| D8 |
35 |
F |
59 |
Vulva |
Squamous cell carcinoma |
II |
Malignant |
| D9 |
36 |
M |
54 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
| E1 |
37 |
F |
85 |
Skin |
Cancer adjacent tissue (with hyperplasia of epithelium) |
- |
Malignant |
| E2 |
38 |
F |
47 |
Esophagus |
Squamous cell carcinoma |
II |
Malignant |
| E3 |
39 |
M |
51 |
Larynx |
Squamous cell carcinoma |
I |
Malignant |
| E4 |
40 |
M |
63 |
Lung |
Squamous cell carcinoma |
III |
Malignant |
| E5 |
41 |
M |
81 |
Lip |
Squamous cell carcinoma |
I |
Malignant |
| E6 |
42 |
M |
50 |
Penis |
Squamous cell carcinoma |
I |
Malignant |
| E7 |
43 |
F |
40 |
Uterine cervix |
Squamous cell carcinoma |
II |
Malignant |
| E8 |
44 |
F |
56 |
Vulva |
Squamous cell carcinoma |
I |
Malignant |
| E9 |
45 |
F |
42 |
Stomach |
Squamous cell carcinoma |
III |
Malignant |
| F1 |
46 |
M |
53 |
Kidney |
Squamous cell carcinoma |
I |
Malignant |
| F2 |
47 |
F |
55 |
Uterus |
Squamous cell carcinoma |
III |
Malignant |
| F3 |
48 |
F |
72 |
Ovary |
Squamous cell carcinoma |
III |
Malignant |
| F4 |
49 |
F |
57 |
Tongue |
Squamous cell carcinoma |
I |
Malignant |
| F5 |
50 |
M |
57 |
Lip |
Squamous cell carcinoma |
I |
Malignant |
| F6 |
51 |
M |
49 |
Ear |
Squamous cell carcinoma (sparse) |
III |
Malignant |
| F7 |
52 |
M |
78 |
Salivary gland |
Squamous cell carcinoma |
III |
Malignant |
| F8 |
53 |
F |
47 |
Breast |
Squamous cell carcinoma |
III |
Malignant |
| F9 |
54 |
F |
50 |
Thymus |
Squamous cell carcinoma |
III |
Malignant |
| G1 |
55 |
F |
50 |
Rectum |
Squamous cell carcinoma |
III |
Malignant |
| G2 |
56 |
M |
42 |
Gallbladder |
Squamous cell carcinoma with necrosis |
III |
Malignant |
| G3 |
57 |
M |
74 |
Bladder |
Squamous cell carcinoma |
I |
Malignant |
| G4 |
58 |
M |
50 |
Ureter |
Squamous cell carcinoma |
III |
Malignant |
| G5 |
59 |
M |
56 |
Eye |
Squamous cell carcinoma |
III |
Malignant |
| G6 |
60 |
M |
57 |
Pharynx |
Squamous cell carcinoma |
I |
Malignant |
| G7 |
61 |
M |
52 |
Nasopharynx |
Squamous cell carcinoma |
III |
Malignant |
| G8 |
62 |
M |
42 |
Nose |
Squamous cell carcinoma |
III |
Malignant |
| G9 |
63 |
M |
47 |
Nose |
Cancer adjacent tissue (chronic inflammation with hyperplasia |
- |
Malignant |
, . † For precise diagnosis, refer to pathology description.
**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.
Staining Scoring: '-' - no staining; '+-' - borderline staining; '+' - weak staining; '++' - moderate staining; '+++' - strong staining; '%' - percentage of positive cells.
TNM grading:
T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum
N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes
M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis
|
|
|
|
|
|
